Kanesaki T, Baba K, Tsuda N, Yabuuchi H, Yamanishi K, Takahashi M
Biken J. 1986 Dec;29(3-4):63-71.
A live attenuated mumps and trivalent measles-rubella-mumps (MRM) vaccines have been applied to 887 and 148 children with various underlying diseases at the vaccine clinic of Osaka University Hospital between 1975 and 1985, respectively. Clinical reactions after mumps vaccination occurred in only 7 children (0.8%) and those after MRM vaccination in 28 children (19%), but their underlying diseases were not deteriorated by either vaccination. Clinical follow up study revealed that 2 of the 430 children immunized with mumps vaccine had contracted the disease during 7 year period and 2 of the 123 children immunized with MRM vaccine had contracted clinical mumps or rubella during 3 year period. The seroconversion rates after mumps vaccination were 70% and 61% by the hemagglutination inhibition (HI) test and neutralization (NT) test, respectively, while 94% by the fluorescent antibody to membrane antigen (FAMA) test. Those after MRM vaccination were 87% for measles, 96% for rubella by the HI test and 89% for mumps by the FAMA test. Serological follow up study revealed that antibodies elicited by mumps vaccination were sustained without substantial decline for at least 7 years. These results suggest that a live attenuated mumps and MRM vaccines are safe and effective in children with various underlying diseases.
1975年至1985年间，大阪大学医院疫苗门诊分别对887名和148名患有各种基础疾病的儿童接种了减毒活腮腺炎疫苗和三价麻疹-风疹-腮腺炎（MRM）疫苗。接种腮腺炎疫苗后仅7名儿童（0.8%）出现临床反应，接种MRM疫苗后28名儿童（19%）出现临床反应，但两种疫苗接种均未使他们的基础疾病恶化。临床随访研究显示，430名接种腮腺炎疫苗的儿童中有2名在7年期间感染了腮腺炎，123名接种MRM疫苗的儿童中有2名在3年期间感染了临床腮腺炎或风疹。腮腺炎疫苗接种后的血凝抑制（HI）试验和中和（NT）试验的血清转化率分别为70%和61%，而膜抗原荧光抗体（FAMA）试验的血清转化率为94%。MRM疫苗接种后，HI试验的麻疹血清转化率为87%，风疹为96%，FAMA试验的腮腺炎血清转化率为89%。血清学随访研究显示，腮腺炎疫苗接种所诱导的抗体至少持续7年无明显下降。这些结果表明，减毒活腮腺炎疫苗和MRM疫苗对患有各种基础疾病的儿童是安全有效的。
